Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Trade Show

iProov Launches Brand New Cross-Platform Biometric: Palm Verifier


iProov, a leading provider of biometric authentication technology and genuine presence assurance, today announces the launch of its Palm Verifier product at Finovate Europe 2019.

For the very first time, users will be able to use palm verification on any of their personal devices, either as a standalone mode of authentication or as an additional authentication factor, with strong assurance of genuine presence.

The launch provides a new choice for consumers, employees and enterprises, enabling them to select the secure, device-independent biometric they prefer. For example, users can authenticate themselves using Palm Verifier when conducting high value transactions, attempting to access personal information like medical records, using remote ATMs or gaining physical access to unsupervised remote sites.

Users simply hover their palm above their device and Palm Verifier will authenticate them in under 5 seconds. The process is fast, flexible and hygienic and is also exceptionally easy, intuitive and inclusive to use.

For certain users and in a number of cultures, face verification is neither a preferred nor an accessible mode of authentication. For these users, Palm Verifier will deliver an anonymous, easy, yet highly secure authentication experience that can be used in all light conditions. Unlike faces, palm prints are not shared on social media or stored in government records therefore do not provide traceable clues back to the identity of the user. This means for some users; Palm Verifier's key benefit is its anonymity.

Palm Verifier is protected by the genuine presence assurance capabilities of iProov's patented Flashmark technology. As recently endorsed by the UK National Physical Laboratory (NPL), iProov's Flashmark-based one-time biometrics uniquely protect against spoof and replay attacks. Replay attacks, arising from social engineering and malware, are a particular hazard to consumers.

iProov Face Verifier has already been comprehensively proven in field and laboratory tests to be strongly resistant to the full range of spoof attacks, including 3D solid artefacts. Palm Verifier has the same strong Genuine Presence Assurance, whilst awaiting scale testing of solid artefacts which pose a low hazard thanks to the anonymity of palms.

Andrew Bud, Founder and CEO of iProov, said, "Our mission is to create a safe and secure digital environment, in which users feel protected and organisations can trust in the genuine presence of their remote customer.

Palm authentication is an exciting new way to establish trust in digital interaction and support diverse user preferences. Palm Verifier is more than just a great technology innovation, it provides customers with more freedom to choose their method of authentication whilst assuring the genuine presence of their online identity.

-ends-

About iProov

Founded in 2011 by CEO Andrew Bud, iProov is a world leader in spoof-resistant, biometric facial verification technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine and to guard them against fraudulent attempts to gain access to personal data or use a stolen identity. For more information, please see www.iproov.com


These press releases may also interest you

19 avr 2019
Golden Pearl Mushrooms Ltd. is recalling GPM brand Pea Shoots from the marketplace due to possible Listeria monocytogenes contamination. Consumers should not consume the recalled products described below. The following products have been sold in...

19 avr 2019
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 21, 2019 to file lead plaintiff applications in a securities class action lawsuit against Healthcare Services Group, Inc. , if they purchased the...

19 avr 2019
The U.S. Food and Drug Administration today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS)...

19 avr 2019
Maxinovel Pharmaceuticals, Inc. presented in the 2019 AACR the head to head comparison of its orally active small molecule PD-L1 inhibitor with commercially marketed PD-L1 antibody drug Durvalumab in the human PD-L1 knock-in MC38...

19 avr 2019
DataFile Technologies announced today it is joining the Strategic Health Information Exchange Collaborative (SHIEC) group purchasing program to provide healthcare data services via the DataFile Velocity Exchange. In response to a recent RFI, DataFile...

19 avr 2019
Brandon M. Lingenfelter, DO, PhD is recognized by Continental Who's Who as a Top Doctor in the field of Medicine in recognition of his role as an OB-GYN at Brandon M. Lingenfelter, DO, PhD and Princeton Community Hospital. A frontrunner in the...



News published on 11 february 2019 at 19:05 and distributed by: